Crow Point Partners’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Crow Point Partners’s Portfolio NBRV Stock Details NBRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$143K	Buy	+434	New	+$199K	0.22%	68

Other funds holding NBRV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Crow Point Partners's NBRV Position: Q4 2019 in Review

Crow Point Partners opened a new position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q4 2019: 434 shares worth $143K. The stake represents 0.22% of the portfolio and ranks #68 among its holdings.

50 funds tracked by Wall St. Rank hold NBRV as of Q4 2019.

Crow Point Partners held 434 shares of Nabriva Therapeutics plc Ordinary Shares Ireland worth $143K as of Q4 2019.
Nabriva Therapeutics plc Ordinary Shares Ireland was a new Crow Point Partners position in Q4 2019.
Nabriva Therapeutics plc Ordinary Shares Ireland made up 0.22% of Crow Point Partners's portfolio in Q4 2019, its #68 holding.
50 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q4 2019.

Based on Crow Point Partners's 13F filing for Q4 2019, filed 14 Feb 2020.